XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange (opens original article in a new tab)

XORTX Therapeutics has decided to voluntarily delist from the TSX Venture Exchange, citing cost and regulatory inefficiencies, while maintaining Nasdaq listing for shareholder trading.

• XORTX Therapeutics has elected to voluntarily delist from the TSX Venture Exchange.
• The decision follows a review indicating that maintaining a dual listing is not cost-effective due to regulatory and administrative challenges.
• Shareholders will retain trading access on Nasdaq without needing to take action.